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doi:10.1Objective: Increasingly, patients with previous sternotomy require aortic valve replacement. We compared out-
comes of reoperative aortic valve replacement after previous sternotomy and primary aortic valve replacement by
surgical era. Effect of initial cardiac operation on reoperative aortic valve replacement was also investigated.
Methods: Between January 1996 and December 2007, a total of 1603 patients undergoing elective aortic valve
replacement were entered prospectively into our clinical database. Patients were divided into eras A (1996–1999),
B (2000–2003), and C (2004–2007). A total of 191 patients (12%) had previous sternotomy for coronary artery
bypass grafting (n ¼ 88), coronary artery bypass grafting with aortic valve replacement (n ¼ 16), aortic valve
replacement with or without other aortic procedure (n ¼ 70), and other cardiac procedures (n ¼ 17). Mean
ages were 66.5  13.1 years in reoperative group and 65.5  14.9 years in primary group.
Results: Mortality in reoperative group decreased significantly with time (A 15.4% vs B 15.1% vs C 2.0%, P¼
.004) and was equivalent to primary group in era C (3.5% vs 2.0%, P ¼ .65). Major complications also signif-
icantly decreased with time in reoperative group (A 25.6% vs B 17.0% vs C 6.1%, P ¼ .006). Importantly,
patients had more comorbidities with time and increased preoperative risk in era C. There were no differences
in outcome by initial cardiac operation in reoperative group.
Conclusions: Reoperative aortic valve replacement now carries similar morbidity and mortality to primary re-
placement. Risk of reoperation is not affected by primary operation. (J Thorac Cardiovasc Surg 2010;139:263-72)Aortic valve replacement (AVR) is a frequently performed
operation in the United States. According to the Society of
Thoracic Surgeons (STS) national database, approximately
12,000 to 18,000 cases of isolated AVR and a similar num-
ber of AVR procedures with concomitant coronary artery
bypass grafting (CABG) are performed annually.1 The oper-
ative mortalities for isolated AVR now approach 3%,
whereas the mortality for AVR with CABG is approxi-
mately 5%.1 With a rising elderly population and improve-
ments in surgical management of disease, patients are living
longer after cardiac surgery and facing increasing preopera-
tive risks. Consequently, a higher percentage of patients
with aortic valve disease are likely to undergo reoperative
AVR in the foreseeable future. Furthermore, advancing
technology with the use of percutaneous valves has recently
emerged for the treatment of aortic valve disease in high-risk
patients.
In the past, reoperative AVR was considered a high-risk
operation. Previous studies have demonstrated mortalitiese Department of Surgery, University of Virginia, Charlottesville, Va.
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The Journal of Thoracic and Cafor reoperative AVR to range from 5.9% to 14%.2-4 Recent
trends, however, have demonstrated improved outcomes for
reoperative AVR.5,6 Accordingly, we compared operative
outcomes of reoperative AVR with primary AVR by surgi-
cal era. We hypothesized that reoperative AVR would dem-
onstrate similar risks to primary AVR with respect to
operative mortality and major complications.MATERIALS AND METHODS
Patients
This investigation was approved by the human investigation committee
of the University of Virginia Health System (HSR 14077), including
a waiver of the need to obtain patient consent. Data from all patients under-
going aortic valve operations at our institution were entered prospectively
into the STS database. A retrospective review was then performed of all pa-
tients undergoing AVR from January 1996 to December 2007. Primary
AVR occurred in the absence of a previous sternotomy or cardiac operation
while reoperative AVRs followed a previous sternotomy for cardiac opera-
tion. We stratified patients according to extent of cardiac operation to further
delineate any effects of concomitant operations. Further, to evaluate the im-
pact of the initial operation, patients undergoing reoperative AVR were cat-
egorized into 4 groups according to previous cardiac operation: (1) CABG
only, (2) CABG with AVR, (3) AVR with or without other aortic operation,
and (4) other cardiac procedures. In addition, reoperative AVRs were di-
vided into 3 operative eras (A, 1996–1999; B, 2000–2003; C, 2004–
2007) to assess the impact of operative era on AVR.
Patient demographic characteristics, preoperative risk factors, operative
features, and postoperative outcomes were examined over time. STS defini-
tions were used to describe all preoperative variables, postoperative compli-
cations, and outcomes. Standard and logistic EuroSCOREs were calculated
to evaluate preoperative risk. The method used to calculate the STS pre-
dicted risk of mortality has undergone multiple changes and revisionsrdiovascular Surgery c Volume 139, Number 2 263
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
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a risk score for many patients undergoing concomitant operations. We there-
fore chose not to use that risk assessment model in our data analyses. Oper-
ative mortality included patient deaths occurring before hospital discharge
or within 30 days after the operation. Major complications included the
composite incidence of postoperative renal failure, stroke, and pneumonia.
Statistical Analysis
The primary outcomes measured were operative mortality and major
complication rate for patients undergoing primary and reoperative AVR. Pa-
tients undergoing reoperative AVR were further analyzed with respect to
operative era as well as initial operation. All patient group comparisons
were unpaired. Categoric variables were analyzed by bivariate comparisons
with either c2 test or Fisher’s Exact Test as indicated. Analysis of variance
was used for all continuous variables.
Multivariable logistic regression was performed to estimate the odds of
death associated with reoperative AVR. All preoperative variables entered
as covariates (male sex, peripheral vascular disease, cerebrovascular dis-
ease, endocarditis, chronic renal insufficiency, chronic lung disease, coro-
nary artery disease, and operative era) were selected a priori according to
established clinical risk in cardiac operations. The estimated odds of death
were adjusted for all covariates. The discrimination achieved by these
models was assessed with the C statistic, which is equivalent to the area un-
der the receiver operating characteristic curve. C statistic values of 1.0 indi-
cate perfect discrimination between survivors and decedents, whereas
values of 0.5 indicate results equal to chance.
All categoric variables are expressed as percentage of group of origin,
and continuous variables are expressed as mean  SD. Odds ratios with
95% confidence intervals are used to report the results of the logistic regres-
sion. All P values reported are 2-tailed. Data manipulation and analysis were
performed with SAS version 9.1.3 software (SAS Institute, Inc, Cary, NC).
RESULTS
Comparison of Primary and Reoperative AVR
During an 11-year study period, a total of 1603 patients
underwent AVR at the University of Virginia. Within this
cohort, 1412 primary AVRs and 191 reoperative AVRs
were performed (Table 1). The average patient age was sim-
ilar between primary and reoperative AVR groups. The reo-
perative AVR group contained more male patients than did
the primary AVR group and had higher rates of preoperative
peripheral vascular disease, diabetes, dyslipidemia, coro-
nary artery disease, endocarditis, and chronic renal insuffi-
ciency. Conversely, patients undergoing primary AVR
were in New York Heart Association functional class IV
more commonly than were patients undergoing reoperative
AVR.
Operative features also differed between primary and re-
operative AVR groups (Table 1). Patients in the primary
AVR group underwent significantly more isolated AVR
operations than did those in the reoperative AVR group.264 The Journal of Thoracic and Cardiovascular SurgPatients undergoing reoperative AVR had higher rates of
concomitant CABG and mitral valve procedures than did
those undergoing primary AVR. The primary AVR group
underwent more aortic root replacements and pulmonic
valve procedures than did the reoperative AVR group. The
reoperative AVR group also underwent placement of more
early mechanical valves than did the primary AVR group.
Aortic crossclamp times were shorter in reoperative AVRs
than in primary AVRs, whereas cardiopulmonary bypass
times were similar between groups.
Few differences in postoperative outcomes were observed
between groups. Overall major complication rates were
equivalent between primary and reoperative AVR groups
(15.2% [214/1412] vs 15.2% [29/191], respectively, P ¼
.92). Patients undergoing primary AVR had significantly
higher rates of sepsis (2.9% [41/1412] vs 0.0% [0/191],
P ¼ .01), atrial fibrillation (23.9% [337/1412] vs 13.6%
[26/191], P ¼ .001), and prolonged ventilation (10.0%
[141/1,412] vs 3.7% [7/191], P ¼ .003) than did those un-
dergoing reoperative AVR. Total hospital stay (9.0  9.6
days vs 9.1  9.7 days, P ¼ .89) and intensive care unit
stay (3.3 7.3 days vs 4.1 8.5 days, P¼ .15) were similar
between primary and reoperative AVR groups. In an analy-
sis of isolated AVR operations, higher rates of major compli-
cations (16.0% [181/1131] vs 8.7% [9/104], P¼ .04), atrial
fibrillation (24.6% [278/1131] vs 15.4% [16/104], P ¼
.04), and prolonged ventilation (10.9% [123/1131] vs
2.9% [3/104], P ¼ .01) were observed among patients un-
dergoing primary AVR than among patients undergoing
reoperative AVR.
The overall operative mortality for reoperative AVR was
higher than for primary AVR (8.4% [16/191] vs 4.1% [58/
1412], P ¼ .02). Among the subgroup of patients undergo-
ing isolated AVR, higher overall operative mortality was
also observed for reoperative AVR than for primary AVR
(8.7% [9/104] vs. 4.1% [46/1131], P ¼ .04).
Influence of Initial Operation on Reoperative AVR
An analysis of all reoperative AVR cases (n ¼ 191) strat-
ified by initial cardiac operation revealed that 88 patients
(46.1%) had undergone previous CABG only, 16 patients
(8.4%) had undergone previous CABG and AVR, 70 pa-
tients (36.6%) had undergone previous AVR with or with-
out other aortic procedures, and 17 patients (8.9%) had
undergone other previous cardiac procedures. Postoperative
outcomes were similar among these reoperative AVR
groups despite differences in initial cardiac operation. Spe-
cifically, major complication rates were not statistically dif-
ferent after initial CABG only (14.8% [13/88]), CABG and
AVR (25.0% [4/16]), AVR with or without other aortic pro-
cedures (8.6% [6/70]), and other cardiac procedures (23.5%
[4/17], P ¼ .80). Operative mortality also did not differ sta-
tistically among initial operation groups: CABG only 5.7%
(5/88), CABG and AVR 18.8% (3/16), AVR with orery c February 2010
TABLE 1. Preoperative risk factors and operative features for patients undergoing primary versus reoperative aortic valve replacement
(n ¼ 1603)
Variable Primary (n ¼ 1412) Reoperative (n ¼ 191) P value
Preoperative
Age at operation (y, mean  SD) 65.5  14.9 66.5  13.1 .41
Male sex (no.) 862 (61.0%) 140 (73.3%) .001
Peripheral vascular disease (no.) 123 (8.7%) 33 (17.3%) .001
Cerebrovascular disease (no.) 317 (22.4%) 37 (19.4%) .35
Chronic lung disease (no.) 191 (13.5%) 27 (14.1%) .82
Diabetes (no.) 258 (18.3%) 50 (26.2%) .01
Dyslipidemia (no.) 597 (42.3%) 108 (56.5%) <.001
Coronary artery disease (no.) 475 (33.6%) 120 (62.8%) <.001
Hypertension (no.) 827 (58.6%) 111 (58.1%) .94
New York Heart Association functional class (no.)
I 597 (42.3%) 14 (7.3%) <.001
II 360 (25.5%) 104 (54.5%) <.001
III 298 (21.1%) 63 (33.0%) <.001
IV 156 (11.0%) 10 (5.2%) .01
Endocarditis (no.) 61 (4.3%) 15 (7.9%) .04
Chronic renal insufficiency (no.) 154 (10.9%) 32 (16.8%) .02
Operative
Isolated aortic valve replacement (no.) 1,131 (80.1%) 104 (54.5%) <.001
Bioprosthetic valve (no.) 939 (66.5%) 125 (65.5%) .81
Mechanical valve (no.) 299 (21.2%) 55 (28.8%) .02
Homograft (no.) 35 (2.5%) 5 (2.6%) .81
Concomitant operations (no.)
Coronary artery bypass grafting 126 (8.9%) 58 (30.4%) <.001
Aortic root operations 132 (9.3%) 9 (4.7%) .04
Mitral valve procedures 69 (4.9%) 22 (11.5%) <.001
Pulmonic valve procedures 37 (2.6%) 0 (0.0%) .02
Tricuspid valve procedures 23 (1.6%) 5 (2.6%) .37
Cardiopulmonary bypass time (min, mean  SD) 137.9  58.8 135.4  46.7 .66
Aortic crossclamp time (min, mean  SD) 101.5  44.2 92.2  38.4 .03
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diac procedures 11.8% (2/17, P ¼ .54).
Outcomes of Reoperative AVR by Operative Era
Reoperative AVRs were analyzed according to operative
era (Table 2). Significantly more reoperative AVRs were
performed in the most recent era. Compared with early oper-
ative eras, patients in the most recent era were older and had
higher preoperative EuroSCOREs. Higher rates of preoper-
ative dyslipidemia, coronary artery disease, and hyper-
tension were also observed in the most recent era.
Alternatively, New York Heart Association functional class
III was more common in the earliest operative era than in the
most recent operative era (era A 48.7% vs era C 31.3%,
P< .001). The duration between the initial operation and
the reoperative AVR was longest in the most recent era.
Other preoperative risk factors, including endocarditis,
were similar over time. Intraoperatively, higher rates of bio-
prosthetic valves were used in era C, whereas mechanical
valves were more frequently used in early eras. Moreover,
both cardiopulmonary bypass time (era A 157.4 47.5 min-
utes vs era C 132.7  44.8 minutes, P ¼ .005) and aorticThe Journal of Thoracic and Cacrossclamp time (era A 108.6  37.2 minutes vs era C
89.4  36.4 minutes, P ¼ .006) decreased significantly
over time.
Operative outcomes for reoperative AVR improved over
time (Table 3). Reoperations for postoperative bleeding or
tamponade, postoperative pneumonia, and postoperative re-
nal failure were more common in earlier operative eras than
in the most recent era. Hospital and intensive care unit stays
were similar across eras. Major complication rate decreased
significantly over time. Operative mortality also decreased
over time; in the most recent era, mortality for reoperative
AVR was similar to that for primary AVR (2.0% [2/99]
vs 3.5% [19/542], P ¼ .65; Figure 1).
Isolated Reoperative AVR by Operative Era
A total of 104 patients (54.5%) underwent isolated reo-
perative AVR (Table 4). Time-related trends observed
among these patients were nearly identical to those among
all reoperative AVR patients. In the most recent operative
era, patients were older and had higher rates of dyslipide-
mia, coronary artery disease, and hypertension. Addition-
ally, patients in the most recent era had higherrdiovascular Surgery c Volume 139, Number 2 265
TABLE 2. Preoperative risk factors and operative features for patients undergoing reoperative aortic valve replacement with respect to operative
era (n ¼ 191)
Variable 1996–1999 (n ¼ 39) 2000–2003 (n ¼ 53) 2004–2007 (n ¼ 99) P value
Preoperative
Age at operation (y, mean  SD) 64.7  12.1 63.6  17.4 68.7  10.3 0.04
Male sex (no.) 25 (64.1%) 42 (79.2%) 73 (73.7%) 0.27
Peripheral vascular disease (no.) 3 (7.7%) 7 (13.2%) 23 (23.2%) 0.06
Cerebrovascular disease (no.) 4 (10.3%) 10 (18.9%) 23 (23.2%) 0.22
Chronic lung disease (no.) 10 (25.6%) 7 (13.2%) 10 (10.1%) 0.06
Diabetes (no.) 11 (28.2%) 9 (17.0%) 30 (30.3%) 0.20
Dyslipidemia (no.) 10 (25.6%) 22 (41.5%) 76 (76.8%) <.001
Coronary artery disease (no.) 12 (30.8%) 26 (49.1%) 82 (82.8%) <.001
Hypertension (no.) 15 (38.5%) 28 (52.8%) 68 (68.7%) .003
New York Heart Association functional class (no.)
I 7 (17.9%) 5 (9.4%) 2 (2.0%) .004
II 10 (25.6%) 30 (56.6%) 64 (64.6%) <.001
III 19 (48.7%) 13 (24.5%) 31 (31.3%) .04
IV 3 (7.7%) 5 (9.4%) 2 (2.0%) .11
Endocarditis (no.) 4 (10.3%) 5 (9.4%) 6 (6.1%) .63
Chronic renal insufficiency (no.) 3 (7.7%) 7 (13.2%) 22 (22.2%) .09
Ejection fraction (%, mean  SD) 44.0  14.9 57.7  14.9 47.4  14.3 <.001
EuroSCORE (logistic, mean  SD) 19.6  1.8 18.8  1.6 25.4  1.9 <.001
EuroSCORE (standard, mean  SD) 9.4  0.4 9.5  0.3 10.8  0.3 <.001
Time to reoperation (y, mean  SD) 9.6  0.8 11.5  1.0 12.1  0.9 <.001
Operative
Isolated aortic valve replacement (no.) 19 (48.7%) 30 (56.6%) 55 (55.6%) .72
Bioprosthetic valve (no.) 16 (41.0%) 34 (64.2%) 75 (75.8%) .001
Mechanical valve (no.) 19 (48.7%) 14 (26.4%) 22 (22.2%) .01
Homograft (no.) 1 (2.6%) 3 (5.7%) 1 (1.0%) .23
Concomitant operations (no.)
Coronary artery bypass grafting 15 (38.5%) 12 (22.6%) 31 (31.3%) .25
Aortic root operations 0 (0.0%) 3 (5.7%) 6 (6.1%) .30
Mitral valve procedures 6 (15.4%) 9 (17.0%) 7 (7.1%) .13
Pulmonic valve procedures 0 (0.0%) 0 (0.0%) 0 (0.0%) NA
Tricuspid valve procedures 0 (0.0%) 0 (0.0%) 4 (4.0%) .15
Cardiopulmonary bypass time (min, mean  SD) 157.4  47.5 131.6  58.7 132.7  44.8 .18
Aortic crossclamp time (min, mean  SD) 108.6  37.2 95.1  53.6 89.4  36.4 .21
NA, Not applicable.
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monary bypass time (era A 137.2  37.9 minutes vs era
C 115.7  37.5 minutes, P ¼ .04) and aortic crossclamp
time (era A 91.7  20.9 minutes vs era C 73.8  31.5 min-
utes, P ¼ .02) were significantly shorter in the most recent
era. Decreased rates of postoperative pneumonia, prolonged
ventilation, and renal failure were noted over time among
patients undergoing isolated reoperative AVR. Operative
mortality also decreased significantly with time for isolated
reoperative AVR and within the most recent era was equiv-
alent to that of isolated primary AVR (0.0% [0/55] vs 3.3%
[16/486], P ¼ .39).
Factors Related to Mortality in Reoperative AVR
A total of 16 (8.4%) patients in the reoperative AVR
group died: 7 patients (43.8%) of postoperative bleeding
or tamponade, 3 patients (18.8%) of multiorgan failure,266 The Journal of Thoracic and Cardiovascular Surg2 patients (12.5%) of cardiac arrest, 2 patients (12.5%)
of heart failure, 1 patient (6.3%) of respiratory failure,
and 1 patient (6.3%) of stroke. All 6 deaths in era A
(100%) occurred after elective repeat AVR, whereas
75% of deaths in era B (6/8) occurred after urgent AVR
and 25% (2/8) after emergency AVR. Within era C, all
deaths (100% [2/2]) occurred after urgent AVR. Signifi-
cantly more deaths occurred after urgent, reoperative
AVR in the recent eras (era A 0.0% vs era B 75.0% vs
era C 100.0%, P ¼ .01).
Univariate analyses (Table 5) of all risk factors related to
mortality in reoperative AVR revealed that coronary artery
disease and hypertension were paradoxically more frequent
among patients who had survived than among those who
died. Higher preoperative EuroSCOREs were noted for pa-
tients who died. All other risk factors were similar between
groups. Patients who died had longer cardiopulmonaryery c February 2010
TABLE 3. Postoperative outcomes for patients undergoing reoperative aortic valve replacement with respect to operative era (n ¼ 191)
Variable 1996–1999 (n ¼ 39) 2000–2003 (n ¼ 53) 2004–2007 (n ¼ 99) P value
Sepsis (no.) 0 (0.0%) 0 (0.0%) 0 (0.0%) NA
Stroke (no.) 2 (5.1%) 4 (7.5%) 4 (4.0%) .65
Cardiac arrest (no.) 1 (2.6%) 1 (1.9%) 1 (1.0%) .79
Reoperation for bleeding or tamponade (no.) 1 (2.6%) 8 (15.1%) 5 (5.1%) .03
Atrial fibrillation (no.) 7 (17.9%) 7 (13.2%) 12 (12.1%) .66
Heart block (no.) 0 (0.0%) 0 (0.0%) 3 (3.0%) .24
Gastrointestinal event (no.) 1 (2.6%) 0 (0.0%) 1 (1.0%) .49
Pneumonia (no.) 3 (7.7%) 5 (9.4%) 0 (0.0%) .01
Prolonged ventilation (no.) 3 (7.7.%) 3 (5.7%) 1 (1.0%) .11
Renal failure (no.) 5 (12.8%) 4 (7.5%) 2 (2.0%) .04
Hemodialysis (no.) 1 (2.6%) 2 (3.8%) 0 (0.0%) .17
Hospital stay (d, mean  SD) 10.6  8.3 8.9  11.5 8.7  9.2 .58
Intensive care unit stay (d, mean  SD) 4.8  6.9 4.3  9.8 3.8  8.5 .83
Major complications (no.) 10 (25.6%) 9 (17.0%) 6 (6.1%) .006
Operative mortality (no.) 6 (15.4%) 8 (15.1%) 2 (2.0%) .004
NA, Not applicable.
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other operative features were similar between groups.
A multivariable logistic regression analysis examining the
outcome of operative mortality among patients undergoing
reoperative AVR identified early operative era as the only
significant predictor of mortality (odds ratio 7.39, 95% con-
fidence interval 1.432–38.115, P ¼ .02). The model
achieved adequate discrimination with a C statistic of 0.796.
DISCUSSION
In this study, we corroborated current evidence suggest-
ing recent declines in operative mortality and major compli-
cation rate associated with reoperative AVR. The
reoperative AVR group had higher rates of preoperative co-
morbidities. Despite this elevated risk, the observed opera-
tive mortalities for both isolated reoperative AVR and
reoperative AVR with concomitant operations significantly
decreased with time and in the most recent era were compa-
rable to those of primary AVR. Among patients undergoing
reoperative AVR, we were unable to identify any significant
differences related to the initial cardiac operation. Moreover,FIGURE 1. Mortality and major cofmplication rate for patients un
The Journal of Thoracic and Cawe identified early operative era as a significant predictor of
mortality for patients undergoing reoperative AVR. We be-
lieve these results have the potential to change the status of
reoperative AVR surgery.
Many studies have identified risk factors during reopera-
tive AVR. Cardiac surgery in the elderly population adds
risk to the patient.7,8 Other operative risk factors that have
been identified include female sex, weight, cardiac func-
tional class, endocarditis, reduced ejection fraction, periph-
eral vascular disease, renal insufficiency, concomitant
CABG, number of coronary artery bypasses, prosthetic
valve type or thrombosis, other cardiac valve disease, hemo-
dynamic instability, and ascending aortic aneurysm re-
pair.2,9-13
Despite having more risk factors and undergoing more
concomitant CABG or mitral valve procedures, our reoper-
ative AVR group had shorter aortic crossclamp times than
did our primary AVR group. The longer aortic crossclamp
times in primary AVRs may result from the higher percent-
age of aortic root operations performed in this population.
Otherwise, crossclamp times among reoperative AVRsdergoing aortic valve replacement as function of operative era.
rdiovascular Surgery c Volume 139, Number 2 267
TABLE 4. Preoperative risk factors, operative features, and postoperative outcomes for patients undergoing isolated reoperative aortic valve
replacement with respect to operative era (n ¼ 104)
Variable 1996–1999 (n ¼ 19) 2000–2003 (n ¼ 30) 2004–2007 (n ¼ 55) P value
Preoperative
Age at operation (y, mean  SD) 59.3  14.8 62.5  20.6 69.4  11.1 .02
Male sex (no.) 12 (63.2%) 23 (76.7%) 44 (80.0%) .33
Peripheral vascular disease (no.) 3 (15.8%) 5 (16.7%) 15 (27.3%) .41
Cerebrovascular disease (no.) 1 (5.3%) 6 (20.0%) 11 (20.0%) .31
Chronic lung disease (no.) 6 (31.6%) 5 (16.7%) 6 (10.9%) .11
Diabetes (no.) 4 (21.1%) 7 (23.3%) 17 (30.9%) .62
Dyslipidemia (no.) 3 (15.8%) 14 (46.7%) 44 (80.0%) <.001
Coronary artery disease (no.) 7 (36.8%) 17 (56.7%) 43 (78.2%) .003
Hypertension (no.) 6 (31.6%) 16 (53.3%) 42 (76.4%) .001
New York Heart Association functional class (no.)
I 5 (26.3%) 3 (10.0%) 1 (1.8%) .004
II 3 (15.8%) 16 (53.3%) 34 (61.8%) .002
III 10 (52.6%) 7 (23.3%) 19 (34.5%) .11
IV 1 (5.3%) 4 (13.3%) 1 (1.8%) .09
Endocarditis (no.) 3 (15.8%) 2 (6.7%) 4 (7.3%) .47
Chronic renal insufficiency (no.) 1 (5.3%) 2 (6.7%) 10 (18.2%) .17
Ejection fraction (%, mean  SD) 45  16.1 53.9  13.2 47.9  15.5 .09
EuroSCORE (logistic, mean  SD) 20.1  8.4 18.3  11.3 27.5  18.2 .02
EuroSCORE (standard, mean  SD) 10.2  1.9 9.6  2.2 11.1  3.0 .04
Operative
Bioprosthetic valve (no.) 5 (26.3%) 19 (63.3%) 45 (81.8%) <.001
Mechanical valve (no.) 11 (57.9%) 6 (20.0%) 10 (18.2%) .002
Homograft (no.) 0 (0.0%) 3 (10.0%) 0 (0.0%) NA
Cardiopulmonary bypass time (min, mean  SD) 137.2  37.9 95.5  28.6 115.7  37.5 .16
Aortic crossclamp time (min, mean  SD) 91.7  20.9 58.8  11.7 73.8  31.5 .17
Outcome
Sepsis (no.) 0 (0.0%) 0 (0.0%) 0 (0.0%) NA
Stroke (no.) 0 (0.0%) 2 (6.7%) 2 (3.6%) .50
Cardiac arrest (no.) 0 (0.0%) 1 (3.3%) 1 (1.8%) .71
Reoperation for bleeding or tamponade (no.) 0 (0.0%) 3 (10.0%) 1 (1.8%) .11
Atrial fibrillation (no.) 4 (21.1%) 3 (10.0%) 9 (16.4%) .56
Heart block (no.) 0 (0.0%) 0 (0.0%) 1 (1.8%) .64
Gastrointestinal event (no.) 0 (0.0%) 0 (0.0%) 0 (0.0%) NA
Pneumonia (no.) 0 (0.0%) 5 (16.7%) 0 (0.0%) .002
Prolonged ventilation (no.) 0 (0.0%) 3 (10.0%) 0 (0.0%) .02
Renal failure (no.) 1 (5.3%) 2 (6.7%) 1 (1.8%) .51
Hemodialysis (no.) 0 (0.0%) 2 (6.7%) 0 (0.0%) .08
Hospital stay (d, mean  SD) 8.4  4.9 10.4  15.0 7.6  4.2 .40
Intensive care unit stay (d, mean  SD) 3.5  5.6 5.9  12.6 2.8  2.2 .18
Major complications (no.) 1 (5.3%) 5 (16.7%) 3 (5.5%) .18
Operative mortality (no.) 3 (15.8%) 6 (20.0%) 0 (0.0%) .003
NA, Not applicable.
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improved operative technique and efficiency with time.
Recent series have documented improved operative mor-
tality (<5%) for reoperative AVR.5,6,14 These trends are
consistent with our results; we report an overall operative
mortality of 8.4% for reoperative AVR, which decreased
to 2.0% in the most recent era. Not surprisingly, univariate
analyses demonstrated longer aortic crossclamp and cardio-
pulmonary bypass times for patients who died. The pro-
longed exposure to cardiopulmonary bypass of patients268 The Journal of Thoracic and Cardiovascular Surgundergoing reoperative AVR likely contributed to the
increased overall mortality among these patients. The
concurrent decrease in mortality associated with shorter car-
diopulmonary bypass and aortic crossclamp times in the
most recent era further suggests that prolonged pump and
crossclamp times in the early operative eras grossly affected
operative survival among patients undergoing reoperative
AVR during that time.
There are important trends to note among patients under-
going reoperative AVR. We performed significantly moreery c February 2010
TABLE 5. Univariate analyses of preoperative risk factors and operative features for mortality in patients undergoing reoperative aortic valve
replacement (n ¼ 191)
Variable Survived (n ¼ 175) Died (n ¼ 16) P value
Preoperative
Age at operation (y, mean  SD) 66.4  13.0 67.6  15.1 .71
Male sex (no.) 130 (74.3%) 10 (62.5%) .38
Peripheral vascular disease (no.) 32 (18.3%) 1 (6.3%) .31
Cerebrovascular disease (no.) 34 (19.4%) 3 (18.8%) >.99
Chronic lung disease (no.) 22 (12.6%) 5 (31.3%) .06
Diabetes (no.) 47 (26.9%) 3 (18.8%) .57
Dyslipidemia (no.) 102 (58.3%) 6 (37.5%) .12
Coronary artery disease (no.) 114 (65.1%) 6 (37.5%) .05
Hypertension (no.) 107 (61.1%) 4 (25.0%) .01
New York Heart Association functional class (no.)
I 11 (6.3%) 3 (18.8%) .10
II 99 (56.6%) 5 (31.3%) .07
III 57 (32.6%) 6 (37.5%) .78
IV 8 (4.6%) 2 (12.5%) .20
Endocarditis (no.) 13 (7.4%) 2 (12.5%) .36
Chronic renal insufficiency (no.) 29 (16.6%) 3 (18.8%) .74
Ejection fraction (%, mean  SD) 47.5  14.1 48.3  10.4 .92
EuroSCORE (logistic, mean  SD) 22.8  15.4 30.2  21.7 .05
EuroSCORE (standard, mean  SD) 10.3  2.7 11.2  3.4 .17
Operative
Isolated aortic valve replacement (no.) 95 (54.3%) 9 (56.3%) >.99
Bioprosthetic valve (no.) 117 (66.9%) 8 (50.0%) .18
Mechanical valve (no.) 51 (29.1%) 4 (25.0%) >.99
Homograft (no.) 2 (1.1%) 3 (18.8%) .004
Concomitant operations (no.)
Coronary artery bypass grafting 53 (30.3%) 5 (31.3%) >.99
Aortic root operations 8 (4.6%) 1 (6.3%) .55
Mitral valve procedures 20 (11.4%) 2 (12.5%) >.99
Pulmonic valve procedures 0 (0.0%) 0 (0.0%) NA
Tricuspid valve procedures 5 (2.9%) 0 (0.0%) >.99
Cardiopulmonary bypass time (min, mean  SD) 132.9  43.1 209.5  89.4 .001
Aortic crossclamp time (min, mean  SD) 90.4  35.9 145.3  73.3 .01
NA, Not applicable.
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eras A and B. Although New York Heart Association func-
tional class IV was more common in the early operative era,
patients in the most recent era were older and had higher pre-
operative EuroSCOREs. Consequently, these patients were
sicker and carried higher preoperative risk than did those
in the earlier eras. In addition, decreases in complications
and mortality occurred in conjunction with an increase in
the number of reoperative AVR cases at our institution.
This is consistent with evidence that suggests that high-vol-
ume cardiac centers report improved operative outcomes.15
Otherwise, improvements in cardiac anesthesia, operative
techniques (including less extensive dissection), and postop-
erative care likely played a fundamental role in our enhanced
operative outcomes and decreased mortality over time.
Recently, we demonstrated no differences in postoperative
outcomes or mortality in reoperative cardiac surgery afterThe Journal of Thoracic and CaCABG with avoidance of clamping the internal thoracic ar-
tery.16 It is possible that this change in reoperative technique
and minimal dissection may have contributed to the
decreases in complication rates and mortality that we ob-
served during the most recent operative era.
The effect of initial cardiac operation on reoperative
AVR outcomes remains ill defined. Reoperative aortic
valve surgery after previous CABG17 or AVR18 has in the
past been associated with elevated risk of morbidity and
mortality. Some studies, however, have recently demon-
strated that previous CABG does not significantly increase
mortality risk in reoperative AVR.19-21 These results are
consistent with our observations that CABG and CABG
with AVR as the initial operation did not significantly affect
rates of postoperative complications or operative mortality
relative to previous isolated AVR or other cardiac valve
operations.rdiovascular Surgery c Volume 139, Number 2 269
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DCurrent treatment options for both primary and reopera-
tive aortic valve surgery vary greatly. Options include aortic
valve repair, traditional AVR with either biologic or me-
chanical prosthetic valves, pulmonary autograft (Ross pro-
cedure), and, most recently, transcatheter aortic valve
implantation. In this study, insufficient numbers of aortic
valve repair and Ross autograft procedures were performed
to warrant useful statistical analyses. All AVRs performed
among reoperative patients were open procedures with ei-
ther bioprosthetic or mechanical valves. No percutaneous
or transapical AVRs were performed during this study pe-
riod. Early experience with percutaneous and transapical
AVRs in high-risk patients with aortic valve disease have
been mixed. Mortalities after percutaneous and transapical
AVR have ranged from 7% to 14% in recent series.22-25
Relative to our reoperative AVR cohort, these mortality rates
remain significantly elevated. Because the high-risk opera-
tive group in which percutaneous aortic valves are currently
being used differs from reoperative AVR candidates, further
investigation into the outcomes of these techniques will be
required before advocating this technology as a primary ap-
proach to reoperative AVR.
Several paradoxic findings emerged during this study.
We observed shorter aortic crossclamp times and lower
rates of postoperative atrial fibrillation among patients
undergoing reoperative AVR than among those undergo-
ing primary AVR, as well as higher rates of coronary ar-
tery disease and hypertension among survivors of
reoperative AVR survivors than among those who died.
Unfortunately, we are unable to explain these results
completely because of the admittedly small sample sizes
of these study cohorts. We are thus constrained in our ef-
forts to attribute any true clinical significance to these
findings.
There are several limitations to this study. First, the retro-
spective nature of this study introduces inherent bias, and we
are limited by variables that are collected in the STS data-
base. Second, this study included a heterogeneous cohort.
All patients undergoing an AVR were included during the
referenced study period, regardless of concomitant cardiac
operation. Because the numbers and types of concomitant
operations varied among patients, small differences related
to specific concomitant operations were difficult to assess.
Third, the confounding effects of different operating sur-
geons over time were difficult to determine and may have
influenced the trends observed in this study. Similarly,
changes over time in both cardiac anesthesia and postopera-
tive care are difficult to account for in data analyses. Finally,
the total number of patients undergoing reoperative AVR
was admittedly small relative to those undergoing primary
AVR. Our ability to detect small differences between the
groups was therefore limited, and our ability to define risk
factors for reoperative AVR more clearly was constrained.
Nevertheless, the observed trends in markedly improved270 The Journal of Thoracic and Cardiovascular Surgpostoperative complications and operative mortality among
reoperative patients undergoing AVR during the recent era
corroborates the important clinical contribution of this study
to recently published data. In addition, our findings indicat-
ing improved results as our experience grew suggest that
these high-risk procedures should be performed at high-vol-
ume centers.CONCLUSIONS
In this study, reoperative AVR in the current era has been
shown to carry similar morbidity and mortality to those of
primary AVR. Risks of reoperation were unaffected by the
initial cardiac operation. We therefore believe that reopera-
tive AVR should be considered a safe operation for patients
requiring surgical treatment for aortic valve disease after
a previous sternotomy.
We thank Curtis Klann and Judy Smith for their assistance with
the STS Database search and data collection.References
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Dr Leonard N. Girardi (New York, NY). I congratulate Dr La-
Par for an excellent presentation and the University of Virginia
group for outstanding results in a patient population that we are
all seeing more of, those with previous cardiac surgery now requir-
ing AVR. The 2% mortality in their last 100 cases is truly remark-
able, actually lower than their mortality among patients undergoing
primary AVR. To help us to learn more from their experience and
perhaps incorporate some of their experiences and recommenda-
tions into our own practice, I have a few questions.
Dr LaPar, you were correct in assigning some of the credit for
this improvement in mortality with time to improved surgical tech-
nique and a larger hospital experience with this patient population.
The patients in the last era, however, about the last 100 patients, ac-
tually had better New York Heart Association functional class, had
higher ejection fraction, underwent fewer urgent operations, and
underwent fewer concomitant mitral valve and CABG procedures
at the time of reoperative AVR. So, are we truly technically better
than we were in a previous era, or are we just better at getting pa-
tients to the operating room earlier? That would include educating
our cardiology counterparts in getting patients to the operating
room earlier. Also, once we get them to the operating room, are
we a little smarter not so much in how we do the operation techni-
cally but perhaps in what we don’t do to the mitral valve and to the
coronaries, to cut down on the increased crossclamp and bypass
times that so significantly contributed to mortality in your series?
Dr LaPar. Dr Girardi, thank you for the feedback and those in-
sightful questions. Certainly, patient selection is fundamental in im-
proving operative outcomes and mortality. In this study, we believe
that the trends that we had seen in declining operative mortality andThe Journal of Thoracic and Caoutcomes are likely related to a combination of several factors. As
you mentioned, we performed significantly more reoperative AVRs
in the most recent era. We believe that as we do more surgery, we
are getting better. In addition, the change in our surgical technique
to include a minimal dissection of the heart has contributed to
shorter aortic crossclamping and cardiopulmonary bypass times.
We feel that these effects are significant in our results. We also,
in the most recent times, have obtained more preoperative com-
puted tomographic angiograms to help us to define vein graft anat-
omy better, as well as cardiac and mediastinal anatomy, and we
believe that this may help in that patient selection and also in our
operative planning. Finally, improvements in cardiac anesthesia
and postoperative care with time have likely resulted in benefits
for all cardiac operations.
With respect to preoperative risk, you mentioned ejection frac-
tion and New York Heart Association functional class. We primar-
ily thought to evaluate preoperative risk with EuroSCORE, and we
did find higher EuroSCOREs in the most recent operative era. We
consider higher EuroSCOREs to be representative of a sicker and
older population in the most recent era. To rule out the effects of
concomitant operations, we thought it was important to look at
the isolated reoperative AVR group. We showed nearly identical
trends and improved mortality within that group as well.
Dr Girardi. Second, and finally, if open reoperative AVR is to
remain competitive with the less invasive approaches that we heard
about earlier today, transapical and transfemoral AVR, especially
in reoperations where they may actually have some obvious bene-
fits, we have to continue to work on reducing the morbidity and
mortality. The number one cause of mortality in your series was
bleeding and post operative tamponade. Although in the last era
you had a remarkable 5% reoperation or reexploration rate for
bleeding, 43% of the deaths in this series were from tamponade
and bleeding. So how are you handling that? Also, should we actu-
ally be a bit more aggressive and liberal about taking patients back
for bleeding to avoid those catastrophic consequences of massive
transfusion and unrecognized tamponade?
Dr LaPar. We could not agree more. At our institution, we per-
form early reexploration for all suspected cases of persistent post-
operative bleeding or tamponade. Specifically, we perform early
reexploration in the intensive care unit with standard operating
room equipment, personnel, and procedure. Our philosophy is
that early reexploration will prevent further postoperative compli-
cations and improve patient outcome. Furthermore, we believe
that the higher postoperative bleeding rates of our earlier operative
eras is related to more complex dissections in the past.
Dr Anthony L. Estrera (Houston, Tex). I congratulate you
on a nice presentation. In doing reoperative cardiac surgery,
we also apply this minimal dissection, or what I call directed dis-
section. More than half your cases had previous CABG. So
my question is, how did you deal with the patent left internal
thoracic artery?
Dr LaPar. Thank you for that question. One of the more recent
philosophic changes in our operative techniques is that we do not
routinely clamp the internal thoracic artery during reoperations.
In fact, we recently published a series looking at this issue and
found no difference in outcome or mortality with this technique.
In adopting this approach, we have attained equal results while at
the same time simplifying the operation and avoiding internal tho-
racic artery injury.rdiovascular Surgery c Volume 139, Number 2 271
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nice presentation. I have a question regarding the technique of can-
nulation and how that has evolved with time. Have you used axil-
lary cannulation? If so, how has that influenced outcomes and
neurologic complications?
Dr LaPar. In this study, we did not specifically evaluate out-
comes according to cannulation technique. We routinely use preop-272 The Journal of Thoracic and Cardiovascular Surgerative computed tomographic angiography and intraoperative
ultrasonography, however, to survey the ascending aorta to select
an appropriate aortic cannulation site. Almost all the cases included
in this study involved direct aortic cannulation. For cases in which
aortic cannulation is difficult, we favor such approaches as axillary
or innominate cannulation.ery c February 2010
